BIOMARKERS FOR EARLY SEPSIS DETECTION
With
Dr Gabrielle Briggs
Postdoctoral Researcher and Lab Manager,
School of Medicine and Public Health
The University of Newcastle, New South Wales, Australia
RESEARCHER PROFILE
Filmed in Newcastle, New South Wales, Australia | October 2025
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
Dr Briggs has a strong focus on innovation and translation, building close partnerships between the university and the health service to accelerate the movement of new technologies into clinical practice. Gabrielle played a key role in founding the Hunter Medical Research Institute’s Injury and Trauma Research Program and currently serves as its Deputy Director. Gabrielle is also an enthusiastic educator, teaching the next generation of clinicians in the University of Newcastle’s Joint Medical Program.
Source: Supplied
https://orcid.org/0000-0002-9117-4772
-
Pregnancy in women with chronic kidney disease
Professor Shilpanjali Jesudason is an academic nephrologist and Head of Department at the Royal Adelaide Hospital’s Central Northern Adelaide Renal and Transplant Service, South Australia.
From 2017-2020, she was the Clinical Director of Kidney Health Australia, the peak body for patients with kidney disease. In this role she developed a passion for advancing kidney disease education in primary care.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
